Last reviewed · How we verify
NCT06912542: DM2
ACUTE EFFECT OF CONSUMPTION OF GROUND OR WHOLE FLAXSEEDS ON BLOOD GLUCOSE IN PEOPLE WITH TYPE 2 DIABETES
NA trial testing Whole flaxseed bread in Diabetes in 16 participants. Completed in 21 December 2023.
21 December 2023
Quick facts
| Lead sponsor | Universidade Francisca |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 8 May 2023 |
| Primary completion | 21 December 2023 |
| Estimated completion | 21 December 2023 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Whole flaxseed bread
- Ground flaxseed bread
- French bread
Conditions studied
- Diabetes — all drugs for Diabetes →
- Diabetes Type 2 — all drugs for Diabetes Type 2 →
- Insulin Resistance — all drugs for Insulin Resistance →
Sponsor
Universidade Francisca
Who can join
18 and older, any sex, with Diabetes or Diabetes Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to evaluate the effect of consuming a portion of French bread combined with whole or ground flaxseed on the glycemia of people with DM 2 in a randomized, crossover clinical trial conducted with 16 people with DM 2 who were not using insulin. The main questions of the study were: 1. Is flaxseed able to control the glycemia of people with type 2 diabetes? 2. What is the best way to consume flaxseed to control the glycemia of people with type 2 diabetes? The 3 types of bread (whole flaxseed, ground flaxseed and control) were evaluated in interventions, with a 7-day interval between them, for the consumption of the bread and evaluation of the behavior of the glycemia and insulin curve.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06912542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06912542 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidade Francisca
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06912542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing